Category: Press Release - Page 31 - Psychedelic Alpha

Read more about the article Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

Post published:January 25, 2023
Post category:Press Release

Read more about the article GH Research Provides Business Updates and Highlights Key Upcoming Milestones

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Post published:January 25, 2023
Post category:Press Release

Read more about the article Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

Post published:January 24, 2023
Post category:Press Release

Read more about the article Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin

Post published:January 24, 2023
Post category:Press Release

Read more about the article Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Post published:January 24, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Post published:January 23, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Post published:January 20, 2023
Post category:Press Release

Read more about the article Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Post published:January 20, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Post published:January 20, 2023
Post category:Press Release

Read more about the article MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MYDECINE INNOVATIONS GROUP FILES PROSPECTUS SUPPLEMENT AND ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

Post published:January 20, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.